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Abstract
The Commission for Hospital Hygiene and Infection Control (KRINKO)
at the Robert Koch-Institute Berlin published the “Recommendations
Commission for
Hospital Hygiene and
for Preventing and Controlling Methicillin-Resistant Staphylococcus Infection Prevention at aureus (MRSA) Strains in Hospitals and Other Medical Facilities“ in the
the Robert Koch-
Institute
1 Federal Health Gazette in 1999 [1]. These recommendations were
translatedforthecurrenteditionofGMSKrankenhaushygieneInterdis-
ziplinär by the German Society of Hospital Hygiene.
KRINKO's work is legitimated by § 23 para. 2 of the Infection Protection
Act. Regarding the legal nature of the KRINKO recommendations, it
1 Berlin, Germany
should be noted that they are neither a formal act or an administrative
regulation.
The KRINKO recommendations are instead an evidence-based con-
sensus of particularly qualified experts. The consensus is reached by
includingtheFederalStates'authoritiesandallcompetentprofessional
bodies and associations. This is to guarantee that the KRINKO recom-
mendations reflect the state-of-the-art of medical science, and are met
with a high degree of user acceptance. The recommendations are
publishedintheFederalHealthGazetteandontheRKI'sInternetpages
(http://www.rki.de/).
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Zusammenfassung
Die Kommission für Krankenhaushygiene und Infektionsprävention
(KRINKO)beimRobertKoch-InstitutBerlin)hat1999die„Empfehlungen
zurPräventionundKontrollevonMethicillin-resistentenStaphylococcus-
aureus-(MRSA)-Stämmen in Krankenhäusern und anderen medizini-
schen Einrichtungen“ im Bundesgesundheitsblatt veröffentlicht [1].
Diese Empfehlung wurde für die vorliegende Ausgabe von GMS Kran-
kenhaushygiene Interdisziplinär von der Deutschen Gesellschaft für
Krankenhaushygiene übersetzt.
Die Arbeit der KRINKO ist über den § 23 Abs. 2 des Infektionsschutzge-
setzes legitimiert. Bezüglich des Rechtscharakters der Empfehlungen
der KRINKO ist festzuhalten, dass es sich dabei weder um ein Gesetz
noch um eine Verwaltungsvorschrift handelt.
VielmehrstellendieEmpfehlungenderKRINKOeinenEvidenz-basierten
Konsens besonders qualifizierter Fachleute dar, wobei die Konsensbil-
dung unter Einbeziehung der Kompetenz der Bundesländer und aller
zuständigen Fachgesellschaften und -verbände erfolgt. Damit soll ge-
währleistet werden, dass die Empfehlungen der KRINKO den aktuellen
Stand der medizinischen Wissenschaft wiedergeben und auf hohe Ak-
zeptanz bei den Anwendern stoßen. Die Empfehlungen werden im
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Guideline OPEN ACCESSBundesgesundheitsblatt sowie auf den Internetseiten des RKI
(http://www.rki.de/) veröffentlicht.
Recommendations
1 Introduction
Alongside the increasing importance of Staphylococcus
aureusasapathogeninnosocomialinfections,resistance
toaseriesofantibioticshasconsiderablyandincreasingly
deteriorated. Methicillin-resistance in S. aureus, i.e. the
insensitivity of the pathogen to so-called staphylococcal-
efficientpenicillinase-fastpenicillins(isoxazolyl-penicillin),
currently constitutes a resistance mechanism which is
particularly problematic for clinical practice. Methicillin
(oxacillin)-resistant S. aureus (MRSA, ORSA) strains are
not only resistant to all β-lactam antibiotics (penicillins,
cephalosporins and carbapenems) but also tend to
demonstratethephenomenonofmulti-resistance,i.e.an
insensitivitytosubstancespertainingtoseveralantibiotic
classes.TherapeuticoptionsforMRSAinfectionsarethus
radically restricted, and MRSA infections are becoming
a significant risk factor for patients concerned [2]. The
spread of MRSA strains with additionally decreased gly-
copeptidesensitivity(vancomycin-intermediateS.aureus
= VISA) as observed at present, especially in Japan and
the US, would critically limit controllability of MRSA infec-
tions due to the loss of the therapeutic glycopeptide op-
tion [3], [4].
The intrinsic methicillin-resistance is based on the
methicillin-resistance determinant which is integrated in
the bacterial chromosome and carries the mecA gene
encodingamodifiedpenicillin-bindingprotein(PBP).This
so-calledPBP2a(PBP2')conditionsthephenotypiccorrel-
ate of methicillin resistance due to its lowered affinity for
β-lactam antibiotics [5]. In case of doubt, the detection
of the mecA gene by means of molecular biological
methods(e.g.polymerasechainreaction(PCR))confirms
the MRSA character of an S. aureus isolate.
MRSA infections are an escalating problem within in-pa-
tient facilities all over the world. Aside from countries
where the MRSA situation can barely be controlled any
longer (amongst others, Japan, USA, Spain, Italy, France
andEngland)withashareofbetween20and60percent
MRSA, countries which have been able to restrict their
MRSA incidences to a few percentage points as a result
of strict control and prevention strategies (the Nether-
lands, Scandinavian countries) should also be noted [6].
Regarding Germany, two multi-centre studies with S.
aureusisolates,whichwerecarriedoutinthelateeighties
and early nineties give evidence of an alarming increase
in the MRSA incidence from 3.7% and 1.7% to 8.0%
compared with 1995 figures [7], [8], [9]. If S. aureus
isolates from intensive care areas are examined separ-
ately incidence rates are, in fact, much higher reaching
10.4% and 13.5% [7], [8].
Staphylococcus aureus is of significance both as an im-
portant cause of infections acquired outside hospital
(amongstothers,endocarditis,haematogenousosteomy-
elitis, pneumonia) and especially nosocomial infections.
However, it is also found in the physiological skin flora of
humanswhereitprimarilycolonisesthevestibulesofthe
nose. Some 20% of the population is permanently colon-
isedwithS.aureuswhilstapproximately60%iscolonised
intermittently. Starting from the anterior nares, the
pathogen can spread to other areas of the skin (hands
(!), axilla, perineal region and others) and mucous mem-
branes (pharynx and others). MRSA is thus mainly trans-
mitted from the rhinopharynx of the colonised/infected
patient;furthersourcesofinfectionareintertriginousskin
areas, respiratory secretions, wound exudation and also
blood in the case of bacteriaemiae [10], [11].
Theparticularsituationofhospitalhygieneinconjunction
with the occurrence of MRSA is characterised by the
primary transmission of MRSA through hands of medical
staff, the possibility of months of persistence in case of
nasal colonisations and/or infections with this pathogen
as well as by high environmental resistance of S. aureus.
The pathogen features high resistance to dryness and
heat, and is viable in the inanimate environment (e.g.
gowns, air, surfaces of devices, instruments, personal
care products, hospital inventory etc.) for months [12].
Decisive measures for controlling MRSA situations
include:
• early recognition and verification of MRSA strains;
• systematic(cohort)isolationofMRSAcolonised/infec-
ted patients;
• extensive information and training of staff;
• strict adherence to general hygiene measures (hand
disinfection (!), and others);
• eradication of nasal MRSA colonisation.
Further consequences for dealing with MRSA patients
areavoidinginvasive-diagnosticandoperative(especially
elective) procedures as far as possible and minimising
transfer and transport. It is only through timely and ad-
equate measures to control infection that transmissions
of MRSA can be prevented, outbreaks of MRSA can be
limited and/or the occurrence of endemic situations can
beavertedand,notleast,additionalcostsforthefacilities
concerned can be avoided [13], [14], [15], [16].
The following recommendations of the Commission for
Hospital Hygiene and Infection Prevention at the Robert
Koch-Institute regarding the prevention of MRSA trans-
missionsgivedetailedguidanceonhowtodealwithMRSA
inhealthcarefacilities.Therecommendationshavebeen
classified according to categories [17].
2 General information (Category I B)
• Medical and other staff of healthcare facilities is to be
trained to understand the importance of and know how
to deal with MRSA colonised and/or infected patients,
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specific hygiene measures are adhered to.
• If an MRSA colonisation and/or infection is reasonably
suspected or evident, the hospital hygienist, staff in
charge of hygiene and the managers of the respective
healthcare facility are to be informed imminently.
• Close contact with infectious diseases consultants is
the prerequisite for optimum MRSA management.
3Spatial-functionalrequirementsofthe
accommodation of MRSA patients
(Category I B)
• MRSA colonised and/or infected patients must be
spatially separated from other patients, preferably in
rooms with ensuite bathrooms and an anteroom. Doors
are to be kept closed.
• Several patients with MRSA may be accommodated
together (cohort isolation).
4 Protection against contamination
(Category I B)
• Rules of hand hygiene are to be strictly observed (even
if disposable gloves are used) (see Guideline for Hospital
Hygiene and Infection Prevention, Appendix 5.1 “Hand
Hygiene”) [18].
•Thegownmustbechangedandamaskcoveringmouth
and nose must be worn when entering the patient room.
The protective gown exclusively reserved for dealing with
MRSA patients must remain in the room or anteroom,
and be placed in appropriate laundry bags at the end of
the shift at latest. The mask covering mouth and nose is
to be worn in order to protect staff. It has to be discarded
as waste in the patient's room or the anteroom when
leaving the room.
• Disposable gloves are required if contact with contam-
inated materials, objects, devices and instruments is
possible. They have to be put on before entering the pa-
tient's room and must be discarded as waste in the pa-
tient's room or anteroom when leaving the room.
• Visitors and staff not belonging to the ward must be
asked to abide by the necessary protective measures.
The measures are to be explained to such persons if ne-
cessary.
• Transport and/or transfer within and outside the ward
and/or facility are to be avoided and limited to cases
where it is strictly necessary (see Points 11 and 12).
5 Disinfection and cleaning
(Category I B)
• Surface disinfection (wet disinfection) is required at
least daily for near-patient areas (bedsteads, bedside
tables, wet areas, door handles and the like); if required,
it must be extended to other surfaces susceptible to
contamination (see Guideline for Hospital Hygiene and
Infection Prevention, Appendix 6.12 [18] “Housekeeping
and Surface Disinfection”).
• All contact surfaces of equipment used on patients
(e.g. heads of ultrasonic scanners, ECG electrodes and
cables) must be wet disinfected with agents of the
DGHM/VAH'slistafterthisequipmenthasbeenusedand
before it is removed from the room.
• Stethoscopes, thermometers and the like are to be
usedinapatient-relatedmannerandaretobedisinfected
immediately after use.
• All instruments (scissors, clamps, forceps etc.) used
on patients are sent for disinfection. In case of central
disinfection, instruments must be transported in closed
receptacles.
• Dishes are cleaned routinely (it is advisable to use an
automatic cleaning device) or discarded.
• Laundry and textiles of MRSA patients are collected
and discarded in the patient room or anteroom in ad-
equate laundry bags. Washing is carried out with an ap-
proved laundry disinfection method according to the
DGHM/VAH's or RKI's guideline [19], [20].
6 Waste disposal (Category I B)
MRSA-containing material and waste which could be
contaminatedwithMRSA,aretobedisposedofaswaste
pertaining to Group B. They are disposed of according to
thehygieneplanbutattheendofaworkingshiftatlatest
(fact sheet on how to avoid and dispose of waste from
public and private health service facilities [18], [20]).
7Interventionsinpatients(CategoryIB)
• Necessary diagnostic and minor therapeutic interven-
tions should be performed in the patient room as far as
this is reasonable.
• Elective and invasive-diagnostic procedures should as
possible be avoided.
• Operative procedures in MRSA colonised and/or in-
fected patients should be handled as per operations of
the C Group, and are to be conducted in the operational
units provided. In case of operation wards which are not
provided with such a unit, the operating schedule should
be structured in such a way that interventions in MRSA
colonised or infected patients are conducted at the end
of operation programmes. In each case, disinfection
measures must be carried out immediately after the
intervention according to the Guideline for Hospital Hy-
giene and Infection Prevention, see Appendices 5.1 and
4.3.3 “Hygiene Requirements in Operations and other
Surgical Procedures” [18].
8 Screening (Category I B)
• It is not necessary to routinely examine patients or
medical staff for MRSA.
• Screening should be conducted in patients (swabs of
vestibules of the nose and, where applicable, of the
pharynx, the perineal region and of wounds)
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anamnesis;
• who are admitted and transferred from facilities
with known endemic and/or presumed MRSA occur-
rence;suchasburncentres,dialysisfacilities,nursing
homesandfromcountrieswithhighMRSAprevalence
(e.g. Southern and Eastern European countries, USA,
Japan, England).
• In case of accumulative evidence of MRSA in several
patients (>2), that can be linked in terms of space and
time, attempts should be made to perform genotyping
(e.g.usingpulsed-fieldelectrophoresis).Incaseofclonal
identity, screening should be conducted by means of
swabs of the vestibules of the nose and the pharynges
of all patients of the treatment unit concerned as well as
ofthemedicalstaffmembersthathavehaddirectcontact
with the MRSA patients.
9 Decolonisation of MRSA carriers
9.1 Patients (Category I B)
• MRSA colonised patients should be decolonised with
antibacterial agents whose clinical efficacy is proven for
this application.
•FordecolonisingnasalMRSAcolonisations,itisrecom-
mended to apply Mupirocin nasal ointment (into both
vestibulesofthenoseandthreetimesdailyoveraperiod
of at least three days). Nasal sanitation usually also re-
duces colonisation in other parts of the body.
• Alternatively and especially in case of a Mupirocin re-
sistance, preparations with antiseptic agents or other lo-
cally applicable antibiotics with proven efficacy (e.g. Ba-
citracin) may be used.
• For decolonising an MRSA colonisation of the skin,
antiseptically active soaps and solutions with proven ef-
ficacyarerecommendedforwhole-bodyandhairwashing
if the skin is intact.
• For preventing recolonisation, bed linen, clothing and
personal care utensils (face cloths and the like) are to be
changed daily, especially after antiseptic whole-body
washing, during sanitation measures. Personal objects
(spectacles, razors, toothbrushes etc.) are to be left in
the room and disinfected and/or exchanged.
9.2 Staff (Category II)
• MRSA carriers among staff should not treat and nurse
patients until decolonisation has been proven. Decolon-
isation is to be recommended in the event of an MRSA
colonisation (see 9.1).
• For efficiency checking, control swabs are to be taken
accordingtothelocalisationthreedaysafterthedecolon-
isation measures have been concluded at the earliest. If
no more MRSA is detected in these control swabs staff
may return on duty in direct patient care. Further checks
are to be arranged after ten days, one month and three
months after the end of the therapy.
10 Lifting isolation (Category I B)
IsolationcanbeliftedforMRSAcolonisedand/orinfected
patients if MRSA-negative swabs confirm successful de-
colonisation on three successive days, and three days
after the treatment has been concluded at the earliest.
11 Measures for transfer and transport
within the hospital (Category I B)
•TransportationofpatientswithMRSAshouldbelimited
to clinical situations where it is strictly required.
• The target facility has to be informed of the MRSA col-
onisation/infection in the patient in advance, so it may
take necessary protective measures.
• If possible, the patient should be bathed or washed
antiseptically (including hair) immediately before trans-
port.
•Transportationshouldtakeplaceonanindividualbasis,
with fresh bed linen and/or hospital clothing or cover.
• Wound infections or lesions are to be covered tightly.
• Patients with nasopharyngeal colonisation must wear
a mask covering mouth and nose.
• Transport staff and staff of the medical speciality de-
partments involved must put on fresh protective gowns
and gloves in case of close contact with MRSA patients,
and disinfect their hands after contact with MRSA pa-
tients. The protective gowns and gloves used are to be
discarded properly after transportation and/or contact
with patients.
• Contact of the MRSA patient with other patients is to
be avoided.
• Treatment and/or examination measures for MRSA
patients should preferably be moved to the end of the
daily schedule; contact surfaces are to be disinfected
afterwards (see Point 5).
•Allcontactsurfacesofthetransportationdeviceand/or
vehicle are to be disinfected directly after transportation
(see Point 5).
12 Additional measures for transferring
patients to other hospitals and/or
facilities (Category I B)
• Each transportation of MRSA patients should only be
authorised in the event of very strict and well-founded
indications.
• The target facility is to be informed on the MRSA colon-
isation/infection before MRSA patients are being trans-
ferred. MRSA findings must be noted down in the accom-
panyingdocumentswhichmustbeclearlymarkedaccord-
ingly. In particular, information on up-to-date MRSA
screening findings must be transmitted.
• If MRSA is only detected upon the patient's admission
to the target facility, the facility where the patient was
previously admitted needs to be informed.
• Hygiene requirements need to be taken into account
when MRSA patients are being transported.
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onisation in the patient, sanitation should be performed
with an antibacterial agent whose clinical efficacy has
been proven for this application (see Point 9.1).
• The accompanying personnel must wear disposable
gloves and protective gowns if direct contact with MRSA
patients is to be expected (see Point 4).
• Upon admission to the target facility, the patient must
be isolated spatially until further control tests for MRSA
colonisation are negative. Cohort isolations instead of
individual isolations are a possibility in larger facilities
whereendemicoccurrencesofMRSAarealreadypresent
(see Points 3 and 10).
• It is compulsory for the accompanying personnel to
hygienicallydisinfecttheirhandsaftertransportation(see
Point 4).
• If known patients are admitted and/or readmitted they
needtobeisolatedfirstofall,andexaminationsforMRSA
are to be carried out. Isolation needs to be maintained
until MRSA colonisation and/or infection can be ruled
out (see Points 3 and 10).
13 Measures regarding discharge
(Category I B)
• Patients should be discharged if their clinical state
makes it possible; as the case may be in spite of MRSA
colonisation.
•Theoutpatientphysiciangivingfurthertreatmentmust
be informed beforehand and should be advised on what
additionalhygienemeasuresaresensibleandmightneed
to be put in practice.
• Patients should be educated that there is no risk for
healthy contact persons (those at risk are, for example,
contact persons with open wounds or eczematous skin,
immunosuppressedpeople).Handingoutaninformation
leaflet is recommended (see below).
Theserecommendationsweredraftedinaworkinggroup
by G. Peters (head of the working group), K. Becker, F.
Kipp (Münster); of the RKI: D. Heuck, A. Nassauer, G.
Unger and W. Witte, by order of the Commission for Hos-
pitalHygieneandInfectionPreventionattheRobertKoch
Institute (RKI) in Berlin.
Information leaflet for MRSA
patients
Name of the patient:
Date:
Duringyourstayinhospital,testresultshaveshowedyou
are carrying a bacterium which is known as MRSA
(methicillin-resistant Staphylococcus aureus). Simple
colonisationwiththisbacteriumposesnoproblemtoyou,
however,thereisariskthatthesebacteriacanworktheir
way from your skin or nasal mucosa into a wound and
thus into your body. This could cause an MRSA infection.
It is also possible that these bacteria are transmitted to
other people (hospital patients and persons with skin le-
sions), and trigger infections in these people. For these
reasons, we would ask you to observe the following in-
structions to stop your MRSA colonisation.
We will inform your family doctor about your MRSA colon-
isation.Ifrequired,heorshewillprescribefurtherneces-
sary antibacterial and disinfectant preparations, which,
forthetimebeing,wewillgiveyoutotakehomewithyou.
Your doctor might also arrange for bacteriological check-
ups for excluding your MRSA colonisation.
Applicationofantibacterialanddisinfectantpreparations
Nose ointment: Turixin
®
Introduce an amount the size of a match-head into each
nostril with a cotton swab or your little finger three times
daily for … days. Afterwards pinch your nose and sub-
sequently massage it with thumb and index. Hands must
be disinfected afterwards.
Hand disinfectant:
Antiseptic soap:
Antiseptic shampoo:
For daily use, please use the aforementioned antiseptic
and disinfectant products instead of your usual personal
hygiene products. After use, always rinse with plenty of
water. If skin irritation should still occur, seek immediate
medical attention from your family doctor. A fresh towel
and fresh underwear and bedclothes must be used each
time after bathing or showering, including after hair
washing. Changed underwear and bedclothes must then
be subject to a thermal (80 to 90 °C) or chemo-thermal
washing procedure. You should only use towels, face
clothsandothertoiletriesforyourownpersonaluse.They
mustbechangeddaily,and/ordisposable,i.e.single-use,
articles must be used.
What does your colonisation mean for
people that come into contact with you
at home?
TheMRSAbacteriumconstitutesnorisktohealthypeople
in the outpatient and domestic areas; you may socialise
with these people as usual.
An infection with MRSA might break out only where con-
tact occurs with people that have open wounds or skin
eczema. This is why you should avoid particularly close
andintimatecontactwiththesepeopleduringyourMRSA-
carrier state. The same goes when dealing with people
at your home who provide professional nursing services
for patients in a hospital.
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